Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04253626 · ClinicalTrials.gov registry record · Phase 3
Comparison of Oral Ferrous Sulfate to Intravenous Ferumoxytol in Antepartum Iron Deficiency Anemia
A Phase 3 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 3
- Development phase
- 83
- Enrollment target
NCT04253626: Completed Phase 3 study, sponsored by Stanford University.
NCT04253626 is a Phase 3 study that has completed, run by Stanford University. The registered enrollment target is 83 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04253626, a Phase 3 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 83 participants
- Enrollment target
Study Summary
Evaluate the extent to which treatment of iron deficiency anemia beyond 24-34 weeks' gestation of pregnancy with intravenous iron increases hemoglobin compared to oral iron. The investigators will test the hypothesis that pregnant women who are anemic in the second and third trimester are more likely to significantly increase their hemoglobin with intravenous iron as opposed to the usual standard of care, oral iron.
Interventions
- DRUG Ferrous Sulfate
- DRUG Ferumoxytol Injection [Feraheme]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2021-01-21 |
| Est. Completion | 2024-07-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04253626
The ClinicalTrials.gov registry entry for NCT04253626 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ferrous Sulfate is the first listed.
NCT04253626 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04253626 about?
NCT04253626 is a clinical study titled "Comparison of Oral Ferrous Sulfate to Intravenous Ferumoxytol in Antepartum Iron Deficiency Anemia". Evaluate the extent to which treatment of iron deficiency anemia beyond 24-34 weeks' gestation of pregnancy with intravenous iron increases hemoglobin compared to oral iron. The investigators will test the hypothesis that pregnant women who are anemic in the second and third trimester are more likel...
What is the current status of trial NCT04253626?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 83 participants. The study started on 2021-01-21. Estimated completion is 2024-07-01.
What interventions are being tested in trial NCT04253626?
The interventions under investigation include: Ferrous Sulfate (DRUG), Ferumoxytol Injection [Feraheme] (DRUG).
Who is sponsoring clinical trial NCT04253626?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.